Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
VERV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.31 - $13.63
Previous CloseN/A
Volume257.30K
Average Volume (3M)1.26M
Market Cap
$518.57M
Enterprise Value$35.67M
Total Cash (Recent Filing)$172.56M
Total Debt (Recent Filing)$69.98M
Price to Earnings (P/E)―
Beta3.33
Next Earnings
May 07, 2025EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.35
Shares Outstanding88,795,770
10 Day Avg. Volume1,017,808
30 Day Avg. Volume1,264,499
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.24
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.10
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$21.43Price Target Upside296.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Management And StrategyThe company's gene editing strategy for cardiovascular disease is supported by a world-class management team, increasing the probability of success for Verve.
Regulatory ApprovalVERVE-102 IND approval reflects FDA's positive view on the benefit/risk profile and unmet need in HeFH and premature Coronary artery disease.
Strategic PartnershipLLY's opt-in decision is seen as a major inflection point for VERV, with broad and long-term implications.
Bears Say
Clinical Trial RisksThe company has guided to providing a data update from heart-2 which will include safety and biomarker data from the cohorts.
Market CompetitionThe company continues to guide to efficacy similar to inclisiran, which has shown significant reduction in PCSK9.
Safety Profile ConcernsVERVE-102 has been dosed in patients without severe adverse events, and has shown confidence in its efficacy profile, mitigating risks associated with the data.
---
Ownership Overview
15.35% Insiders
12.27% Mutual Funds
44.79% Other Institutional Investors
15.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERV FAQ
What was Verve Therapeutics’s price range in the past 12 months?
Verve Therapeutics lowest stock price was $4.30 and its highest was $13.63 in the past 12 months.
What is Verve Therapeutics’s market cap?
Verve Therapeutics’s market cap is $518.57M.
When is Verve Therapeutics’s upcoming earnings report date?
Verve Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 40 days.
How were Verve Therapeutics’s earnings last quarter?
Verve Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.675 by $0.095.
Is Verve Therapeutics overvalued?
According to Wall Street analysts Verve Therapeutics’s price is currently Undervalued.
Does Verve Therapeutics pay dividends?
Verve Therapeutics does not currently pay dividends.
What is Verve Therapeutics’s EPS estimate?
Verve Therapeutics’s EPS estimate is -0.65.
How many shares outstanding does Verve Therapeutics have?
Verve Therapeutics has 88,795,770 shares outstanding.
What happened to Verve Therapeutics’s price movement after its last earnings report?
Verve Therapeutics reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.675. Following the earnings report the stock price went down -1.743%.
Which hedge fund is a major shareholder of Verve Therapeutics?
Currently, no hedge funds are holding shares in VERV
---
Verve Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.43 (296.85% Upside)
$21.43 (296.85% Upside)
Blogger Sentiment
Bullish
VERV Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 69.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.77%
12-Months-Change
Fundamentals
Return on Equity
-36.36%
Trailing 12-Months
Asset Growth
-13.99%
Trailing 12-Months
Company Description
Verve Therapeutics
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
---
VERV Stock 12 Month Forecast
Average Price Target
$21.43
▲(296.85% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering VERV
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-31.05%
reiterated a buy rating 4 days ago
Copying Cory Jubinville, PhD's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -31.05% per trade.
---